 |
|
|
|
|
|
|
|
|
|
|
|
1 to 10 of 10 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Rodríguez-Manotas M. on PAPER: Meng P. et al., 2013, This paper opens a new way to fight AD. It breaks the paradigm in the sense that upregulating,... 16 Apr 2013.
|
|
|
 |
|
|
Rodríguez-Manotas M. on PAPER: Imamura Y. et al., 2013, Recommendation Only. 19 Feb 2013.
|
|
|
|
|
|
Rodríguez-Manotas M. on NEWS: First Crystal Structure of a Presenilin, The existence of such a hole was previously envisioned in our article, where we explained the... 26 Dec 2012.
|
|
|
|
|
|
Rodríguez-Manotas M. on PAPER: Bali J. et al., 2012, Recommendation Only. 13 Sep 2012.
|
|
|
|
|
|
Rodríguez-Manotas M. on NEWS: In Cells, Late- and Early-Onset Alzheimer’s Look Different, Recommendation Only. 13 Sep 2012.
|
|
|
|
|
|
Rodríguez-Manotas M. on PAPER: Rajapaksha TW. et al., 2011, Recommendation Only. 14 Feb 2012.
|
|
|
|
|
|
Rodríguez-Manotas M. on NEWS: Beyond Aβ: Other APP Fragments Affect Neuron Health and Disease, Recommendation Only. 10 Feb 2012.
|
|
|
|
|
|
Rodríguez-Manotas M. on PAPER: Yu H. et al., 2001, Keeping in mind everything that is currently known about PS1 and its main substrate, APP, this... 22 Mar 2011.
|
|
|
|
|
|
Rodríguez-Manotas M. on PAPER: Di Fede G. et al., 2009, There may be a reversible formation of dimers in the APP molecule, before being cleaved by... 2 Mar 2011.
|
|
|
|
|
|
Rodríguez-Manotas M. on PAPER: Li H. et al., 2009, The presenilin hypothesis should be explained taken into account the latest findings from the... 18 May 2010.
|
|
|
|
|
|
|
1 to 10 of 10 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
Check out our upcoming Webinar: 
